Menu

Experience

Aaron Pomeroy

    • OpenText Acquires Recommind 


    • Guardant Health Series D Financing 


    • Johnson Controls Joint Venture Named a Deal of the Year by China Business Law Journal 


    • LookingGlass Acquires Kleissner And Associates 


    • GlobeImmune Initial Public Offering 


    • FibroGen Closes Largest Biotech IPO in 12 Years 


    • Bristol Meyers Enters Agreement with Five Prime 


    • Axovant Completes $362 Million IPO 


    • ERYTECH – $144 Million IPO 


    • SELLAS Life Sciences Group to Merge with Galena Biopharma 


    • SeatGeek Raises $57 Million and Acquires TopTix 


    • Semiconductor Developer Aquantia Closes $71 Million IPO 


    • FORMA Therapeutics $200M Strategic Collaboration Deal with Celgene 


    • Johnson Controls on $7.5 Billion Joint Venture with SAIC's Yanfeng Automotive Trim Systems 


    • SuppreMol GmbH: Acquired by Baxter International 


    • Cooley Advises on Nightstar + NuCana IPOs 


    • GENFIT SA in its Licensing and Collaboration Agreement with Terns Pharmaceuticals 


    • Forty Seven in its Exclusive License Agreement with Ono Pharmaceutical 


    • X4 Pharmaceuticals in its Exclusive License Agreement with Abbisko Therapeutics 


    • Innate Pharma - $79 Million IPO 


    • Fangdd $78 Million – IPO 


    • DocuSign to Acquire AI Technology Provider Seal Software 


    • Fate Therapeutics Licensing and Platform Collaboration with Janssen Biotech 


    • Forbius Agrees to Sell to Bristol Myers Squibb 


    • Opthea – $128 Million IPO 


    • Horizon Therapeutics to Acquire Viela Bio 


    • Merus Enters Collaboration With Eli Lilly to Develop New Generation of Cancer Treatments 


    • Brandwatch Agrees to Sell to Cision for $450 Million 


Contact us

Back to top

© 2021 Cooley LLP and Cooley (UK) LLP. All rights reserved.

Cooley® is a registered service mark of Cooley LLP in the United States and European Union as well as certain other jurisdictions.